Advertisement

Selective Pulmonary Vasodilators

  • Maurice BeghettiEmail author
  • Robin H. Steinhorn
Chapter
  • 4k Downloads

Abstract

Nitric oxide (NO) is synthesized by the enzyme nitric oxide synthase (NOS) as a product of the conversion of l-arginine to l-citrulline. Three NOS isoforms are expressed in the lung, which are characterized by the regulation of their activities and by specific sites and developmental patterns of expression (Shaul 2002). Endothelial NOS (NOS3) is expressed in vascular endothelial cells and is the predominant source of NO production in the pulmonary circulation. Neuronal NOS (NOS1) and inducible NOS (NOS2) are both expressed in the airway epithelium and at low levels in the vascular smooth muscle. Furthermore, the expression of NOS2 can be induced in a variety of pulmonary cell types by exposure to endotoxin or inflammatory cytokines.

Keywords

Nitric Oxide Pulmonary Hypertension Pulmonary Arterial Hypertension Congenital Diaphragmatic Hernia Congenital Diaphragmatic Hernia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Abman SH, Chatfield BA, Hall SL, McMurtry IF (1990) Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth. Am J Physiol 259:H1921–H1927PubMedGoogle Scholar
  2. Abrams D, Schulze-Neick I, Magee AG (2000) Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 84(2):E4PubMedCentralPubMedGoogle Scholar
  3. Affuso F, Palmieri EA, Di Conza P, Guardasole V, Fazio S (2006) Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension. Int J Cardiol 108(3):429–431PubMedGoogle Scholar
  4. Afolayan AJ, Eis A, Teng RJ, Bakhutashvili I, Kaul S, Davis JM, Konduri GG (2012) Decreases in manganese superoxide dismutase expression and activity contribute to oxidative stress in persistent pulmonary hypertension of the newborn. Am J Physiol Lung Cell Mol Physiol 303(10):L870–L879PubMedCentralPubMedGoogle Scholar
  5. Afshar S, Gibson LL, Yuhanna IS, Sherman TS, Kerecman JD, Grubb PH, Yoder BA, McCurnin DC, Shaul PW (2003) Pulmonary NO synthase expression is attenuated in a fetal baboon model of chronic lung disease. Am J Physiol Lung Cell Mol Physiol 284(5):L749–L758PubMedGoogle Scholar
  6. Aikio O, Metsola J, Vuolteenaho R, Perhomaa M, Hallman M (2012) Transient defect in nitric oxide generation after rupture of fetal membranes and responsiveness to inhaled nitric oxide in very preterm infants with hypoxic respiratory failure. J Pediatr 161(3):397–403 e1PubMedGoogle Scholar
  7. Ananthakrishnan M, Barr FE, Summar ML, Smith HA, Kaplowitz M, Cunningham G et al (2009) L-citrulline ameliorates chronic hypoxia-induced pulmonary hypertension in newborn piglets. Am J Physiol Lung Cell Mol Physiol 297(3):L506–L511PubMedGoogle Scholar
  8. Arrigoni FI, Vallance P, Haworth SG, Leiper JM (2003) Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia. Circulation 107(8):1195–1201PubMedGoogle Scholar
  9. Askie LM, Ballard RA, Cutter GR, Dani C, Elbourne D, Field D, Hascoet JM, Hibbs AM, Kinsella JP, Mercier JC, Rich W, Schreiber MD, Wongsiridej PS, Subhedar NV, Van Meurs KP, Voysey M, Barrington K, Ehrenkranz RA, Finer NN (2011) Inhaled nitric oxide in preterm infants: an individual-patient data meta-analysis of randomized trials. Pediatrics 128(4):729–739PubMedCentralPubMedGoogle Scholar
  10. Atz AM, Lefler AK, Fairbrother DL, Uber WE, Bradley SM (2002) Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises. J Thorac Cardiovasc Surg 124(3):628–629PubMedGoogle Scholar
  11. Auten RL, Mason SN, Whorton MH, Lampe WR, Foster WM, Goldberg RN et al (2007) Inhaled ethyl nitrite prevents hyperoxia-impaired postnatal alveolar development in newborn rats. Am J Respir Crit Care Med 176(3):291–299PubMedCentralPubMedGoogle Scholar
  12. Ball MK, Steinhorn RH (2012) Inhaled nitric oxide for preterm infants: a Marksman’s approach. J Pediatr 161(3):379–380PubMedGoogle Scholar
  13. Ballard RA, Truog WE, Cnaan A, Martin RJ, Ballard PL, Merrill JD, Walsh MC, Durand DJ, Mayock DE, Eichenwald EC, Null DR, Hudak ML, Puri AR, Golombek SG, Courtney SE, Stewart DL, Welty SE, Phibbs RH, Hibbs AM, Luan X, Wadlinger SR, Asselin JM, Coburn CE; NO CLD Study Group (2006a) Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med 355(4):343–353Google Scholar
  14. Ballard RA, Truog WE, Cnaan A, Martin RJ, Ballard PL, Merrill JD et al (2006b) Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med 355(4):343–353Google Scholar
  15. Balzer DT, Kort HW, Day RW, Corneli HM, Kovalchin JP, Cannon BC, Kaine SF, Ivy DD, Webber SA, Rothman A, Ross RD, Aggarwal S, Takahashi M, Waldman JD (2002) Inhaled Nitric Oxide as a Preoperative Test (INOP Test I): the INOP Test Study Group. Circulation 106(12 Suppl 1):I76–I81PubMedGoogle Scholar
  16. Barr FE, Macrae D (2010) Inhaled nitric oxide and related therapies. Pediatr Crit Care Med 11(2 Suppl):S30–S36PubMedCentralPubMedGoogle Scholar
  17. Barr FE, Tirona RG, Taylor MB, Rice G, Arnold J, Cunningham G et al (2007) Pharmacokinetics and safety of intravenously administered citrulline in children undergoing congenital heart surgery: potential therapy for postoperative pulmonary hypertension. J Thorac Cardiovasc Surg 134(2):319–326PubMedGoogle Scholar
  18. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS (1994) Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 121(6):409–415PubMedGoogle Scholar
  19. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB et al (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The primary pulmonary hypertension study group. N Engl J Med 334(5):296–302PubMedGoogle Scholar
  20. Barst RJ, Maislin G, Fishman AP (1999) Vasodilator therapy for primary pulmonary hypertension in children. Circulation 99(9):1197–1208PubMedGoogle Scholar
  21. Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L et al (2003a) Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41(12):2119–2125PubMedGoogle Scholar
  22. Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A et al (2003b) Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 73(4):372–382PubMedGoogle Scholar
  23. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S et al (2004) Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169(4):441–447PubMedGoogle Scholar
  24. Barst RJ, Galie N, Naeije R, Simonneau G, Jeffs R, Arneson C et al (2006a) Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 28(6):1195–1203PubMedGoogle Scholar
  25. Barst R, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S (2006b) Sitaxsentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 47(10):2049–2056PubMedGoogle Scholar
  26. Bassler D, Choong K, McNamara P, Kirpalani H (2006) Neonatal persistent pulmonary hypertension treated with milrinone: four case reports. Biol Neonate 89(1):1–5PubMedGoogle Scholar
  27. Beckman JS, Koppenol WH (1996) Nitric oxide, superoxide, and peroxynitrite: the good, the bad and the ugly. Am J Physiol Cell Physiol 271:C1424–C1437Google Scholar
  28. Beghetti M (2004) Congenital heart disease and pulmonary hypertension. Rev Port Cardiol 23(2):273–281PubMedGoogle Scholar
  29. Beghetti M, Hoeper MM, Kiely DG, Carlsen J, Schwierin B, Segal ES et al (2008) Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program. Pediatr Res 64(2):200–204PubMedGoogle Scholar
  30. Bendayan D, Shitrit D, Kramer MR (2008) Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: a pilot study. Respirology 13(6):916–918PubMedGoogle Scholar
  31. Beyer J, Kolditz M, Ewert R, Rubens C, Opitz C, Schellong S et al (2008) L-arginine plasma levels and severity of idiopathic pulmonary arterial hypertension. Vasa 37(1):61–67PubMedGoogle Scholar
  32. Bloch KD, Filippov G, Sanchez LS, Nakane M, de la Monte SM (1997) Pulmonary soluble guanylate cyclase, a nitric oxide receptor, is increased during the perinatal period. Am J Physiol 272:L400–L406PubMedGoogle Scholar
  33. Brennan LA, Steinhorn RH, Wedgwood S, Mata-Greenwood E, Roark EA, Russell JA, Black SM (2003) Increased superoxide generation is associated with pulmonary hypertension in fetal lambs. A role for NADPH oxidase. Circ Res 92:683–691PubMedGoogle Scholar
  34. Cacoub P, Dorent R, Nataf P, Carayon A (1993) Endothelin-1 in pulmonary hypertension. N Engl J Med 329(26):1967–1968PubMedGoogle Scholar
  35. Chang AC, Atz AM, Wernovsky G, Burke RP, Wessel DL (1995) Milrinone: systemic and pulmonary effects in neonates after cardiac surgery. Crit Care Med 23:1907–1914PubMedGoogle Scholar
  36. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF et al (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358(9288):1119–1123PubMedGoogle Scholar
  37. Channick RN, Sitbon O, Barst RJ, Manes A, Rubin LJ (2004) Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 43(12 Suppl S):62S–67SPubMedGoogle Scholar
  38. Chester M, Tourneux P, Seedorf G, Grover TR, Gien J, Abman SH (2009) Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 297(2):L318–L325PubMedCentralPubMedGoogle Scholar
  39. Chotigeat U, Jaratwashirakul S (2007) Inhaled iloprost for severe persistent pulmonary hypertension of the newborn. J Med Assoc Thai 90(1):167–170PubMedGoogle Scholar
  40. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM et al (1992) An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327(2):70–75PubMedGoogle Scholar
  41. Clark RH, Kueser TJ, Walker MW, Southgate WM, Huckaby JL, Perez JA, Roy BJ, Keszler M, Kinsella JP (2000) Low dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. N Engl J Med 342:469–474PubMedGoogle Scholar
  42. Clark RH, Huckaby JL, Kueser TJ, Walker MW, Southgate WM, Perez JA, Roy BJ, Keszler M (2003) Low-dose nitric oxide therapy for persistent pulmonary hypertension: 1-year follow-up. J Perinatol 23:300–303PubMedGoogle Scholar
  43. Coggins MP, Bloch KD (2007) Nitric oxide in the pulmonary vasculature. Arterioscler Thromb Vasc Biol 27(9):1877–1885PubMedGoogle Scholar
  44. Cole FS, Alleyne C, Barks JD, Boyle RJ, Carroll JL, Dokken D, Edwards WH, Georgieff M, Gregory K, Johnston MV, Kramer M, Mitchell C, Neu J, Pursley DM, Robinson WM, Rowitch DH (2011) NIH Consensus Development Conference statement: inhaled nitric-oxide therapy for premature infants. Pediatrics 127(2):363–369PubMedGoogle Scholar
  45. Croom KF, Curran MP (2008) Sildenafil: a review of its use in pulmonary arterial hypertension. Drugs 68(3):383–397PubMedGoogle Scholar
  46. Cummings JJ, Wang H (2001) Nitric oxide decreases lung liquid production via guanosine 3',5'-cyclic monophosphate. Am J Physiol Lung Cell Mol Physiol 280:L923–L929PubMedGoogle Scholar
  47. Davidson D, Barefield ES, Kattwinkel J, Dudell G, Damask M, Straube R, Rhines J, Chang C (1998) Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. Pediatrics 101:325–334PubMedGoogle Scholar
  48. De Luca D, Zecca E, Piastra M, Romagnoli C (2007) Iloprost as ‘rescue’ therapy for pulmonary hypertension of the neonate. Paediatr Anaesth 17(4):394–395PubMedGoogle Scholar
  49. Deruelle P, Grover TR, Abman SH (2005) Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep. Am J Physiol Lung Cell Mol Physiol 289(5):L798–L806PubMedGoogle Scholar
  50. Dobyns EL, Cornfield DN, Anas NG, Fortenberry JD, Tasker RC, Lynch A, Liu P, Eells PL, Griebel J, Baier M, Kinsella JP, Abman SH (1999) Multicenter randomized controlled trial of the effects of inhaled nitric oxide therapy on gas exchange in children with acute hypoxemic respiratory failure. J Pediatr 134(4):406–412PubMedGoogle Scholar
  51. Doran AK, Ivy DD, Barst RJ, Hill N, Murali S, Benza RL (2008) Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. Int J Clin Pract Suppl 160:5–9PubMedGoogle Scholar
  52. Ehlen M, Wiebe B (2003) Iloprost in persistent pulmonary hypertension of the newborn. Cardiol Young 13(4):361–363PubMedGoogle Scholar
  53. Eifinger F, Sreeram N, Mehler K, Huenseler C, Kribs A, Roth B (2008) Aerosolized iloprost in the treatment of pulmonary hypertension in extremely preterm infants: a pilot study. Klin Padiatr 220(2):66–69PubMedGoogle Scholar
  54. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP (2006) NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 5(9):755–768PubMedCentralPubMedGoogle Scholar
  55. Ewert R, Schaper C, Halank M, Glaser S, Opitz CF (2009) Inhalative iloprost – pharmacology and clinical application. Expert Opin Pharmacother 10(13):2195–2207PubMedGoogle Scholar
  56. Farrow KN, Groh BS, Schumacker PT, Lakshminrusimha S, Czech L, Gugino SF, Russell JA, Steinhorn RH (2008a) Hyperoxia increases phosphodiesterase 5 expression and activity in ovine fetal pulmonary artery smooth muscle cells. Circ Res 102(2):226–233PubMedCentralPubMedGoogle Scholar
  57. Farrow KN, Lakshminrusimha S, Reda WJ, Wedgwood S, Czech L, Gugino SF, Davis JM, Russell JA, Steinhorn RH (2008b) Superoxide dismutase restores eNOS expression and function in resistance pulmonary arteries from neonatal lambs with persistent pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 295(6):L979–L987PubMedCentralPubMedGoogle Scholar
  58. Farrow KN, Lakshminrusimha S, Czech L, Groh BS, Gugino SF, Davis JM, Russell JA, Steinhorn RH (2010) Superoxide dismutase and inhaled nitric oxide normalize phosphodiesterase 5 expression and activity in neonatal lambs with persistent pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 299(1):L109–L116PubMedCentralPubMedGoogle Scholar
  59. Farrow KN, Lee KJ, Perez M, Schriewer JM, Wedgwood S, Lakshminrusimha S, Smith CL, Steinhorn RH, Schumacker PT (2012) Brief hyperoxia increases mitochondrial oxidation and increases phosphodiesterase 5 activity in fetal pulmonary artery smooth muscle cells. Antioxid Redox Signal 17(3):460–470PubMedCentralPubMedGoogle Scholar
  60. Fineman JR, Wong J, Morin FC III, Wild LM, Soifer SJ (1994) Chronic nitric oxide inhibition in utero produces persistent pulmonary hypertension in newborn lambs. J Clin Invest 93:2675–2683PubMedCentralPubMedGoogle Scholar
  61. Fliman PJ, deRegnier RA, Kinsella JP, Reynolds M, Rankin LL, Steinhorn RH (2006) Neonatal extracorporeal life support: impact of new therapies on survival. J Pediatr 148(5):595–599PubMedGoogle Scholar
  62. Galie N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A et al (2002) Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39(9):1496–1502PubMedGoogle Scholar
  63. Galie N, Manes A, Branzi A (2004) The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 61(2):227–237PubMedGoogle Scholar
  64. Galie N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM et al (2005) Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 46(3):529–535PubMedGoogle Scholar
  65. Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA et al (2008) Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117(23):3010–3019PubMedGoogle Scholar
  66. Galie N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z et al (2009) Tadalafil therapy for pulmonary arterial hypertension. Circulation 119(22):2894–2903PubMedGoogle Scholar
  67. Garg P (2008) Oral sildenafil for PPHN in neonates: selection of patients remains a dilemma? J Coll Physicians Surg Pak 18(2):132–133PubMedGoogle Scholar
  68. Gaston BM, Carver J, Doctor A, Palmer LA (2003) S-nitrosylation signaling in cell biology. Mol Interv 3(5):253–263PubMedGoogle Scholar
  69. Geggel R, Reid LM (1984) The structural basis for PPHN. Clin Perinatol 11:525–549PubMedGoogle Scholar
  70. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A et al (2003) Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 42(1):158–164PubMedGoogle Scholar
  71. Ghofrani HA, Pepke-Zaba J, Barbera JA, Channick R, Keogh AM, Gomez-Sanchez MA et al (2004a) Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 43(12 Suppl S):68S–72SPubMedGoogle Scholar
  72. Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadas B et al (2004b) Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 44(7):1488–1496PubMedGoogle Scholar
  73. Giaid A (1998) Nitric oxide and endothelin-1 in pulmonary hypertension. Chest 114(3 Suppl):208S–212SPubMedGoogle Scholar
  74. Gorenflo M, Ullmann MV, Eitel K, Gross J, Fiehn W, Hagl S et al (2005) Plasma L-arginine and metabolites of nitric oxide synthase in patients with left-to-right shunt after intracardiac repair. Chest 127(4):1184–1189PubMedGoogle Scholar
  75. Grimminger F, Weimann G, Frey R, Voswinckel R, Thamm M, Bolkow D et al (2009) First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 33(4):785–792PubMedGoogle Scholar
  76. Grover TR, Parker TA, Zenge JP, Markham NE, Kinsella JP, Abman SH (2003) Intrauterine hypertension decreases lung VEGF expression and VEGF inhibition causes pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 284(3):L508–L517PubMedGoogle Scholar
  77. Hallioglu O, Dilber E, Celiker A (2003) Comparison of acute hemodynamic effects of aerosolized and intravenous iloprost in secondary pulmonary hypertension in children with congenital heart disease. Am J Cardiol 92(8):1007–1009PubMedGoogle Scholar
  78. Hanson KA, Burns F, Rybalkin SD, Miller JW, Beavo J, Clarke WR (1998a) Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message. Am J Respir Crit Care Med 158(1):279–288PubMedGoogle Scholar
  79. Hanson KA, Ziegler JW, Rybalkin SD, Miller JW, Abman SH, Clarke WR (1998b) Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. Am J Physiol 275(5 Pt 1):L931–L941PubMedGoogle Scholar
  80. Hibbs AM, Walsh MC, Martin RJ, Truog WE, Lorch SA, Alessandrini E, Cnaan A, Palermo L, Wadlinger SR, Coburn CE, Ballard PL, Ballard RA (2008) One-year respiratory outcomes of preterm infants enrolled in the Nitric Oxide (to prevent) Chronic Lung Disease trial. J Pediatr 153(4):525–529PubMedCentralPubMedGoogle Scholar
  81. Hiramatsu T, Imai Y, Takanashi Y, Hoshino S, Yashima M, Tanaka SA et al (1997) Time course of endothelin-1 and nitrate anion levels after cardiopulmonary bypass in congenital heart defects. Ann Thorac Surg 63(3):648–652PubMedGoogle Scholar
  82. Hoffman TM, Wernovsky G, Atz AM, Kulik TJ, Nelson DP, Chang AC et al (2003) Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation 107(7):996–1002PubMedGoogle Scholar
  83. Hogman M, Frostell C, Arnberg H, Hedenstierna G (1993) Bleeding time prolongation and NO inhalation. Lancet 341:1664–1665PubMedGoogle Scholar
  84. Hrometz SL, Shields KM (2006) Sildenafil citrate for the treatment of pulmonary hypertension. Drugs Today (Barc) 42(12):771–784Google Scholar
  85. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM et al (2004) Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43(12 Suppl S):13S–24SPubMedGoogle Scholar
  86. Humpl T, Reyes JT, Holtby H, Stephens D, Adatia I (2005) Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 111(24):3274–3280PubMedGoogle Scholar
  87. Hunley TE, Kon V (2001) Update on endothelins – biology and clinical implications. Pediatr Nephrol 16(9):752–762PubMedGoogle Scholar
  88. Ikonomidis JS, Hilton EJ, Payne K, Harrell A, Finklea L, Clark L et al (2007) Selective endothelin-A receptor inhibition after cardiac surgery: a safety and feasibility study. Ann Thorac Surg 83(6):2153–2160; discussion 61PubMedGoogle Scholar
  89. Ivy DD, Doran A, Claussen L, Bingaman D, Yetman A (2004) Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. Am J Cardiol 93(7):943–946PubMedCentralPubMedGoogle Scholar
  90. Ivy DD, Claussen L, Doran A (2007) Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil. Am J Cardiol 99(5):696–698PubMedCentralPubMedGoogle Scholar
  91. Ivy DD, Doran AK, Smith KJ, Mallory GB Jr, Beghetti M, Barst RJ et al (2008) Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 51(2):161–169PubMedCentralPubMedGoogle Scholar
  92. Ivy DD, Abman SH, Barst RJ, Berger RM, Bonnet D, Fleming TR, Haworth SG, Raj JU, Rosenzweig EB, Schulze Neick I, Steinhorn RH, Beghetti M (2013) Pediatric pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D117–D126PubMedGoogle Scholar
  93. Jing ZC, Jiang X, Han ZY, Xu XQ, Wang Y, Wu Y et al (2009) Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J 33(6):1354–1360PubMedGoogle Scholar
  94. Jones RL, Qian Y, Wong HN, Chan H, Yim AP (1997) Prostanoid action on the human pulmonary vascular system. Clin Exp Pharmacol Physiol 24(12):969–972PubMedGoogle Scholar
  95. Karatza AA, Bush A, Magee AG (2005) Safety and efficacy of sildenafil therapy in children with pulmonary hypertension. Int J Cardiol 100(2):267–273PubMedGoogle Scholar
  96. Kaukinen S, Ylitalo P, Pessi T, Vapaatalo H (1984) Hemodynamic effects of iloprost, a prostacyclin analog. Clin Pharmacol Ther 36(4):464–469PubMedGoogle Scholar
  97. Kinsella JP, Abman SH (2005) Inhaled nitric oxide therapy in children. Paediatr Respir Rev 6(3):190–198PubMedGoogle Scholar
  98. Kinsella JP, Truog WE, Walsh WF, Goldberg RN, Bancalari E, Maylock DE, Redding GJ, deLemos RA, Sardesai S, McCurnin DC, Moreland SG, Cutter GR, Abman SH (1997) Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. J Pediatr 131:55–62PubMedGoogle Scholar
  99. Kinsella JP, Parker TA, Ivy DD, Abman SH (2003) Noninvasive delivery of inhaled nitric oxide therapy for late pulmonary hypertension in newborn infants with congenital diaphragmatic hernia. J Pediatr 142(4):397–401PubMedGoogle Scholar
  100. Kinsella JP, Cutter GR, Walsh WF, Gerstmann DR, Bose CL, Hart C, Sekar KC, Auten RL, Bhutani VK, Gerdes JS, George TN, Southgate WM, Carriedo H, Couser RJ, Mammel MC, Hall DC, Pappagallo M, Sardesai S, Strain JD, Baier M, Abman SH (2006) Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med 355(4):354–364PubMedGoogle Scholar
  101. Komai H, Adatia IT, Elliott MJ, de Leval MR, Haworth SG (1993) Increased plasma levels of endothelin-1 after cardiopulmonary bypass in patients with pulmonary hypertension and congenital heart disease. J Thorac Cardiovasc Surg 106(3):473–478PubMedGoogle Scholar
  102. Konduri GG (2004) New approaches for persistent pulmonary hypertension of newborn. Clin Perinatol 31(3):591–611PubMedGoogle Scholar
  103. Konduri GG, Solimani A, Sokol GM, Singer J, Ehrenkranz RA, Singhal N, Wright LL, Van Meurs K, Stork E, Kirpalani H, Peliowski A, Group, NINOS (2004a) A randomized trial of early versus standard inhaled nitric oxide therapy in term and near-term newborn infants with hypoxic respiratory failure. Pediatrics 113:559–564Google Scholar
  104. Konduri GG, Kim UO (2009) Advances in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatr Clin North Am 56(3):579–600, Table of ContentsPubMedCentralPubMedGoogle Scholar
  105. Konduri GG, Solimano A, Sokol GM, Singer J, Ehrenkranz RA, Singhal N, Wright LL, Van Meurs K, Stork E, Kirpalani H, Peliowski A, Neonatal Inhaled Nitric Oxide Study Group (2004b) A randomized trial of early versus standard inhaled nitric oxide therapy in term and near-term newborn infants with hypoxic respiratory failure. Pediatrics 113(3 Pt 1):559–564Google Scholar
  106. Konduri GG, Bakhutashvili I, Eis A, Pritchard KA (2007a) Oxidant stress from uncoupled nitric oxide synthase impairs vasodilation in fetal lambs with persistent pulmonary hypertension. Am J Physiol Heart Circ Physiol 292:H1812–H1820PubMedGoogle Scholar
  107. Konduri GG, Vohr B, Robertson C, Sokol GM, Solimano A, Singer J, Ehrenkranz RA, Singhal N, Wright LL, Van Meurs K, Stork E, Kirpalani H, Peliowski A, Johnson Y (2007b) Early inhaled nitric oxide therapy for term and near-term newborn infants with hypoxic respiratory failure: neurodevelopmental follow-up. J Pediatr 150(3):235–240, 240.e1PubMedCentralPubMedGoogle Scholar
  108. Ladha F, Bonnet S, Eaton F, Hashimoto K, Korbutt G, Thebaud B (2005) Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury. Am J Respir Crit Care Med 172(6):|750–756PubMedGoogle Scholar
  109. Lakshminrusimha S, Steinhorn RH (1999) Pulmonary vascular biology during neonatal transition. Clin Perinatol 26(3):601–619PubMedGoogle Scholar
  110. Lakshminrusimha S, Russell JA, Steinhorn RH, Ryan RM, Gugino SF, Morin FC 3rd, Swartz DD, Kumar VH (2006a) Pulmonary arterial contractility in neonatal lambs increases with 100 % oxygen resuscitation. Pediatr Res 59(1):137–141PubMedCentralPubMedGoogle Scholar
  111. Lakshminrusimha S, Russell JA, Wedgwood S, Gugino SF, Kazzaz JA, Davis JM, Steinhorn RH (2006b) Superoxide dismutase improves oxygenation and reduces oxidation in neonatal pulmonary hypertension. Am J Respir Crit Care Med 174(12):1370–1377. Epub 2006 Sep 28PubMedCentralPubMedGoogle Scholar
  112. Lakshminrusimha S, Russell JA, Steinhorn RH, Swartz DD, Ryan RM, Gugino SF, Wynn KA, Kumar VH, Mathew B, Kirmani K, Morin FC 3rd (2007a) Pulmonary hemodynamics in neonatal lambs resuscitated with 21 %, 50 %, and 100 % oxygen. Pediatr Res 62:313–318PubMedCentralPubMedGoogle Scholar
  113. Lakshminrusimha S, Wiseman D, Black SM, Russell JA, Gugino SF, Oishi P, Steinhorn RH, Fineman JR (2007b) The role of nitric oxide synthase-derived reactive oxygen species in the altered relaxation of pulmonary arteries from lambs with increased pulmonary blood flow. Am J Physiol Heart Circ Physiol 293:H1491–H1497PubMedCentralPubMedGoogle Scholar
  114. Lakshminrusimha S, Swartz DD, Gugino SF, Ma CX, Wynn KA, Ryan RM, Russell JA, Steinhorn RH (2009a) Oxygen concentration and pulmonary hemodynamics in newborn lambs with pulmonary hypertension. Pediatr Res 66(5):539–544PubMedCentralPubMedGoogle Scholar
  115. Lakshminrusimha S, Porta NF, Farrow KN, Chen B, Gugino SF, Kumar VH et al (2009b) Milrinone enhances relaxation to prostacyclin and iloprost in pulmonary arteries isolated from lambs with persistent pulmonary hypertension of the newborn. Pediatr Crit Care Med 10(1):106–112PubMedCentralPubMedGoogle Scholar
  116. Lakshminrusimha S, Steinhorn RH, Wedgwood S, Savorgnan F, Nair J, Mathew B, Gugino SF, Russell JA, Swartz DD (2011) Pulmonary hemodynamics and vascular reactivity in asphyxiated term lambs resuscitated with 21 and 100 % oxygen. J Appl Physiol 111(5):1441–1447PubMedCentralPubMedGoogle Scholar
  117. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG (2003) Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 111(8):1201–1209PubMedCentralPubMedGoogle Scholar
  118. Leuchte HH, Baezner C, Baumgartner RA, Bevec D, Bacher G, Neurohr C et al (2008) Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J 32(5):1289–1294PubMedGoogle Scholar
  119. Lin YJ, Markham NE, Balasubramaniam V, Tang JR, Maxey A, Kinsella JP, Abman SH (2005) Inhaled nitric oxide enhances distal lung growth after exposure to hyperoxia in neonatal rats. Pediatr Res 58(1):22–29PubMedGoogle Scholar
  120. Maclean MR, Johnston ED, McCulloch KM, Pooley L, Houslay MD, Sweeney G (1997) Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J Pharmacol Exp Ther 283(2):619–624PubMedGoogle Scholar
  121. MacRitchie AN, Jun SS, Chen Z, German Z, Yuhanna IS, Sherman TS, Shaul PW (1997) Estrogen upregulates endothelial nitric oxide synthase gene expression in fetal pulmonary artery endothelium. Circ Res 81(Sep):355–362PubMedGoogle Scholar
  122. Maiya S, Hislop AA, Flynn Y, Haworth SG (2006) Response to bosentan in children with pulmonary hypertension. Heart 92(5):664–670PubMedCentralPubMedGoogle Scholar
  123. Mata-Greenwood E, Jenkins C, Farrow KN, Konduri GG, Russell JA, Lakshminrusimha S, Black SM, Steinhorn RH (2006) eNOS function is developmentally regulated: uncoupling of eNOS occurs postnatally. Am J Physiol Lung Cell Mol Physiol 290(2):L232–L241PubMedCentralPubMedGoogle Scholar
  124. Mercier J, Hummler H, Durrmeyer H, Sanchez-Luna M, Carnielli V, Field D, Greenough A, Van Overmeire B, Jonsson B, Hallman M, Baldassarre J (2010) Inhaled nitric oxide (iNO) for the prevention of bronchopulmonary dysplasia in preterm babies (EUNO): a randomised controlled trial. Lancet 376:346–354PubMedGoogle Scholar
  125. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S (2002) Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 105(20):2398–2403PubMedGoogle Scholar
  126. Miller OI, Tang SF, Keech A, Pigott NB, Beller E, Celermajer DS (2000) Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised double-blind study. Lancet 356(9240):1464–1469PubMedGoogle Scholar
  127. Mittendorf J, Weigand S, Alonso-Alija C, Bischoff E, Feurer A, Gerisch M et al (2009) Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem 4(5):853–865PubMedGoogle Scholar
  128. Mourani PM, Abman SH (2013) Pulmonary vascular disease in bronchopulmonary dysplasia: pulmonary hypertension and beyond. Curr Opin Pediatr 25(3):329–337PubMedGoogle Scholar
  129. Mourani PM, Ivy DD, Gao D, Abman SH (2004) Pulmonary vascular effects of inhaled nitric oxide and oxygen tension in bronchopulmonary dysplasia. Am J Respir Crit Care Med 170(9):1006–1013PubMedGoogle Scholar
  130. Mourani PM, Sontag MK, Ivy DD, Abman SH (2009) Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr 154(3):379–384, 384.e1-2PubMedCentralPubMedGoogle Scholar
  131. Moya MP, Gow AJ, Califf RM, Goldberg RN, Stamler JS (2002) Inhaled ethyl nitrite gas for persistent pulmonary hypertension of the newborn. Lancet 360(9327):141–143PubMedGoogle Scholar
  132. Muehlethaler V, Kunig A, Seedorf G, Balasubramaniam V, Abman SH (2008) Impaired VEFG and nitric oxide signaling after nitrofen exposure in rat fetal lung explants. Am J Physiol Lung Cell Mol Physiol 294:L110–L120PubMedGoogle Scholar
  133. Muller M, Scholz S, Kwapisz M, Akinturk H, Thul J, Hempelmann G (2003) Use of inhaled iloprost in a case of pulmonary hypertension during pediatric congenital heart surgery. Anesthesiology 99(3):743–744PubMedGoogle Scholar
  134. Nagaya N, Uematsu M, Okano Y, Satoh T, Kyotani S, Sakamaki F et al (1999) Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 34(4):1188–1192PubMedGoogle Scholar
  135. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A et al (2007) Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116(3):238–248PubMedGoogle Scholar
  136. Namachivayam P, Theilen U, Butt WW, Cooper SM, Penny DJ, Shekerdemian LS (2006) Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med 174(9):1042–1047PubMedGoogle Scholar
  137. Neonatal Inhaled Nitric Oxide Study Group (1997a) Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics 99:838–845Google Scholar
  138. Neonatal Inhaled Nitric Oxide Study Group (1997b) Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med 336:597–604Google Scholar
  139. Neonatal Inhaled Nitric Oxide Study Group (2000) Inhaled nitric oxide in term and near-term infants: neurodevelopmental follow-up of the neonatal inhaled nitric oxide study group (NINOS). J Pediatr 136:611–617Google Scholar
  140. Noori S, Friedlich P, Wong P, Garingo A, Seri I (2007) Cardiovascular effects of sildenafil in neonates and infants with congenital diaphragmatic hernia and pulmonary hypertension. Neonatology 91(2):92–100PubMedGoogle Scholar
  141. North AJ, Star RA, Brannon TS, Ujiie K, Wells LB, Lowenstein CJ, Snyder SH, Shaul PW (1994) Nitric oxide synthase type I and type III gene expression are developmentally regulated in rat lung. Am J Physiol Lung Cell Mol Physiol 266:L635–L641Google Scholar
  142. North AJ, Lau KS, Brannon TS, Wu LC, Wells LB, German Z, Shaul PW (1996) Oxygen upregulates nitric oxide synthase gene expression in ovine fetal pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol 270:L643–L649Google Scholar
  143. Oishi P, Sharma S, Grobe A, Azakie A, Harmon C, Johengen M, Hsu J, Fratz S, Black SM, Fineman JR (2007) Alterations in cGMP, soluble guanylate cyclase, phosphodiesterase 5, and B-type natriuretic peptide induced by chronic increased pulmonary blood flow in lambs. Pediatr Pulmonol 42:1057–1071PubMedGoogle Scholar
  144. Okogbule-Wonodi AC, Ibe BO, Yue BW, Hsu S, Raj JU (1998) Phosphodiesterase activity in intrapulmonary arteries and veins of perinatal lambs. Mol Genet Metab 65(3):229–237PubMedGoogle Scholar
  145. Parker TA, Le Cras TD, Kinsella JP, Abman SH (2000) Developmental changes in endothelial nitric oxide synthase expression and activity in ovine fetal lung. Am J Physiol Lung Cell Mol Physiol 278:L202–L208PubMedGoogle Scholar
  146. Pauvert O, Salvail D, Rousseau E, Lugnier C, Marthan R, Savineau JP (2002) Characterisation of cyclic nucleotide phosphodiesterase isoforms in the media layer of the main pulmonary artery. Biochem Pharmacol 63(9):1763–1772PubMedGoogle Scholar
  147. Pearson DL, Dawling S, Walsh WF, Haines JL, Christman BW, Bazyk A, Scott N, Summar ML (2001) Neonatal pulmonary hypertension–urea-cycle intermediates, nitric oxide production, and carbamoyl-phosphate synthetase function. N Engl J Med 344(24):1832–1838PubMedGoogle Scholar
  148. Petkov V, Gentscheva T, Schamberger C, Haberl I, Artl A, Andreae F et al (2006) The vasoactive intestinal peptide receptor turnover in pulmonary arteries indicates an important role for VIP in the rat lung circulation. Ann N Y Acad Sci 1070:481–483PubMedGoogle Scholar
  149. Petrossian E, Parry AJ, Reddy VM, Akkersdijk GP, McMullan DM, Thompson L et al (1999) Endothelin receptor blockade prevents the rise in pulmonary vascular resistance after cardiopulmonary bypass in lambs with increased pulmonary blood flow. J Thorac Cardiovasc Surg 117(2):314–323PubMedGoogle Scholar
  150. Pierce CM, Krywawych S, Petros AJ (2004) Asymmetric dimethyl arginine and symmetric dimethyl arginine levels in infants with persistent pulmonary hypertension of the newborn. Pediatr Crit Care Med 5(6):517–520PubMedGoogle Scholar
  151. Pollock DM, Keith TL, Highsmith RF (1995) Endothelin receptors and calcium signaling. Faseb J 9(12):1196–1204PubMedGoogle Scholar
  152. Prasad S, Wilkinson J, Gatzoulis MA (2000) Sildenafil in primary pulmonary hypertension. N Engl J Med 343(18):1342PubMedGoogle Scholar
  153. Rairigh RL, Cras TDL, Ivy DD, Kinsella JP, Richter G, Horan MP, Fan ID, Abman SH (1998) Role of inducible nitric oxide synthase in regulation of pulmonary vascular tone in the late gestation ovine fetus. J Clin Invest 101(Jan 1):15–21PubMedCentralPubMedGoogle Scholar
  154. Raja SG, Danton MD, MacArthur KJ, Pollock JC (2007) Effects of escalating doses of sildenafil on hemodynamics and gas exchange in children with pulmonary hypertension and congenital cardiac defects. J Cardiothorac Vasc Anesth 21(2):203–207PubMedGoogle Scholar
  155. Reddy MV, Hendricks-Munoz KD, Rajasinghe HA, Petrossian E, Hanley FL, Fineman JR (1997) Post-cardiopulmonary bypass pulmonary hypertension in lambs with increased pulmonary blood flow: a role for endothelin 1. Circulation 95:1054–1061PubMedGoogle Scholar
  156. Roberts JD, Fineman J, Morin FC III, Shaul PW, Rimar S, Schreiber MD, Polin RA, Thusu KG, Zayek M, Zwass MS, Zellers TM, Wylam ME, Gross I, Zapol WM, Heymann MA (1997) Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. N Engl J Med 336:605–610PubMedGoogle Scholar
  157. Rosenzweig EB, Kerstein D, Barst RJ (1999) Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 99(14):1858–1865PubMedGoogle Scholar
  158. Rosenzweig EB, Ivy DD, Widlitz A, Doran A, Claussen LR, Yung D et al (2005) Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 46(4):697–704PubMedGoogle Scholar
  159. Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM (1993) Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 328:399–405PubMedGoogle Scholar
  160. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A et al (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346(12):896–903PubMedGoogle Scholar
  161. Said SI (2008) The vasoactive intestinal peptide gene is a key modulator of pulmonary vascular remodeling and inflammation. Ann N Y Acad Sci 1144:148–153PubMedGoogle Scholar
  162. Said SI, Hamidi SA, Dickman KG, Szema AM, Lyubsky S, Lin RZ et al (2007) Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation 115(10):1260–1268PubMedGoogle Scholar
  163. Saji T, Ozawa Y, Ishikita T, Matsuura H, Matsuo N (1996) Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension. Am J Cardiol 78(2):244–247PubMedGoogle Scholar
  164. Sanchez LS, de la Monte SM, Filippov G, Jones RC, Zapol WM, Bloch KD (1998) Cyclic-GMP-binding, cyclic-GMP-specific phosphodiesterase (PDE5) gene expression is regulated during rat pulmonary development. Pediatr Res 43(2):163–168PubMedGoogle Scholar
  165. Saygili A, Canter B, Iriz E, Kula S, Tunaoglu FS, Olgunturk R et al (2004) Use of sildenafil with inhaled nitric oxide in the management of severe pulmonary hypertension. J Cardiothorac Vasc Anesth 18(6):775–776PubMedGoogle Scholar
  166. Schermuly RT, Stasch JP, Pullamsetti SS, Middendorff R, Muller D, Schluter KD et al (2008) Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 32(4):881–891PubMedGoogle Scholar
  167. Schreiber MD, Gin-Mestan K, Marks JD, Huo D, Lee G, Srisuparp P (2003) Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med 349(22):2099–2107PubMedGoogle Scholar
  168. Schulze-Neick I, Li J, Reader JA, Shekerdemian L, Redington AN, Penny DJ (2002) The endothelin antagonist BQ123 reduces pulmonary vascular resistance after surgical intervention for congenital heart disease. J Thorac Cardiovasc Surg 124(3):435–441PubMedGoogle Scholar
  169. Schulze-Neick I, Hartenstein P, Li J, Stiller B, Nagdyman N, Hubler M et al (2003) Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation 108(Suppl 1):II167–II173PubMedGoogle Scholar
  170. Shaul PW (2002) Regulation of endothelial nitric oxide synthase: location, location, location. Annu Rev Physiol 64:749–774PubMedGoogle Scholar
  171. Shaul PW, Yuhanna IS, German Z, Chen Z, Steinhorn RH, Morin FC 3rd (1997) Pulmonary endothelial NO synthase gene expression is decreased in fetal lambs with pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 272:L1005–L1012Google Scholar
  172. Shaul PW, Afshar S, Gibson LL, Sherman TS, Kerecman JD, Grubb PH, Yoder BA, McCurnin DC (2002) Developmental changes in nitric oxide synthase isoform expression and nitric oxide production in fetal baboon lung. Am J Physiol Lung Cell Mol Physiol 283(6):L1192–L1199. Epub 2002 Jul 07PubMedGoogle Scholar
  173. Shehata SM, Sharma HS, Mooi WJ, Tibboel D (2006) Pulmonary hypertension in human newborns with congenital diaphragmatic hernia is associated with decreased vascular expression of nitric-oxide synthase. Cell Biochem Biophys 44(1):147–155PubMedGoogle Scholar
  174. Sherman TS, Chen Z, Yuhanna IS, Lau KS, Margraf LR, Shaul PW (1999) Nitric oxide synthase isoform expression in the developing lung epithelium. Am J Physiol Lung Cell Mol Physiol 276:L383–L390Google Scholar
  175. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC et al (2002) Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary hypertension. Am J Respir Crit Care Med 165:1–5Google Scholar
  176. Simonneau G, Rubin LJ, Galie N, Barst RJ, Fleming TR, Frost AE et al (2008) Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 149(8):521–530PubMedGoogle Scholar
  177. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P et al (2002) Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40(4):780–788PubMedGoogle Scholar
  178. Skoro-Sajer N, Lang I (2008) The role of treprostinil in the management of pulmonary hypertension. Am J Cardiovasc Drugs 8(4):213–217PubMedGoogle Scholar
  179. Soderling SH, Beavo JA (2000) Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 12(2):174–179PubMedGoogle Scholar
  180. Sokol J, Jacobs SE, Bohn D (2003) Inhaled nitric oxide for acute hypoxemic respiratory failure in children and adults. Cochrane Database Syst Rev (1):CD002787Google Scholar
  181. Solari V, Piotrowska AP, Puri P (2003) Expression of heme oxygenase-1 and endothelial nitric oxide synthase in the lung of newborns with congenital diaphragmatic hernia and persistent pulmonary hypertension. J Pediatr Surg 38(5):808–813PubMedGoogle Scholar
  182. Souza-Silva AR, Dias-Junior CA, Uzuelli JA, Moreno H Jr, Evora PR, Tanus-Santos JE (2005) Hemodynamic effects of combined sildenafil and L-arginine during acute pulmonary embolism-induced pulmonary hypertension. Eur J Pharmacol 524(1–3):126–131PubMedGoogle Scholar
  183. Steinhorn RH (2008) Nitric oxide and beyond: new insights and therapies for pulmonary hypertension. J Perinatol 28(Suppl 3):S67–S71PubMedCentralPubMedGoogle Scholar
  184. Steinhorn RH (2010) Neonatal pulmonary hypertension. Pediatr Crit Care Med 11(2 Suppl):S79–S84PubMedCentralPubMedGoogle Scholar
  185. Steinhorn RH, Martin RJ (2002) Nitric oxide and the developing airway. Am J Physiol Lung Cell Mol Physiol 283:L1190–L1191PubMedGoogle Scholar
  186. Steinhorn RH, Russell JA, Morin FC 3rd (1995) Disruption of cGMP production in pulmonary arteries isolated from fetal lambs with pulmonary hypertension. Am J Physiol Heart Circ Physiol 268:H1483–H1489Google Scholar
  187. Steinhorn RH, Russell JA, Lakshminrusimha S, Gugino SF, Black SM, Fineman JR (2001) Altered endothelium-dependent relaxations in lambs with high pulmonary blood flow and pulmonary hypertension. Am J Physiol Heart Circ Physiol 280:H311–H317PubMedGoogle Scholar
  188. Stocker C, Penny DJ, Brizard CP, Cochrane AD, Soto R, Shekerdemian LS (2003) Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery. Intensive Care Med 29(11):1996–2003PubMedGoogle Scholar
  189. Tessler RB, Zadinello M, Fiori H, Colvero M, Belik J, Fiori RM (2008) Tadalafil improves oxygenation in a model of newborn pulmonary hypertension. Pediatr Crit Care Med 9(3):330–332PubMedGoogle Scholar
  190. Tiktinsky MH, Morin FC III (1993) Increasing oxygen tension dilates fetal pulmonary circulation via endothelium-derived relaxing factor. Am J Physiol Heart Circ Physiol 265:H376–H380Google Scholar
  191. Tissot C, Beghetti M (2009) Review of inhaled iloprost for the control of pulmonary artery hypertension in children. Vasc Health Risk Manag 5(1):325–331PubMedCentralPubMedGoogle Scholar
  192. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L et al (1999) Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 159(6):1925–1932PubMedGoogle Scholar
  193. Tworetzky W, Bristow J, Moore P, Brook MM, Segal MR, Brasch RC, Hawgood S, Fineman JR (2001) Inhaled nitric oxide in neonates with persistent pulmonary hypertension. Lancet 357:118–120PubMedGoogle Scholar
  194. Tzao C, Nickerson PA, Russell JA, Noble BK, Steinhorn RH (2000) Heterogeneous distribution of type I nitric oxide synthase in pulmonary vasculature of ovine fetus. Histochem Cell Biol 114:421–430PubMedGoogle Scholar
  195. Tzao C, Nickerson PA, Russell JA, Gugino SF, Steinhorn RH (2001) Pulmonary hypertension alters soluble guanylate cyclase activity and expression in pulmonary arteries isolated from fetal lambs. Pediatr Pulmonol 31(2):97–105PubMedGoogle Scholar
  196. Vadivel A, Aschner JL, Rey-Parra GJ, Magarik J, Zeng H, Summar M, Eaton F, Thebaud B (2010) L-citrulline attenuates arrested alveolar growth and pulmonary hypertension in oxygen-induced lung injury in newborn rats. Pediatr Res 68(6):519–525PubMedCentralPubMedGoogle Scholar
  197. Van Meurs KP, Wright LL, Ehrenkranz RA, Lemons JA, Ball MB, Poole WK, Perritt R, Higgins RD, Oh W, Hudak ML, Laptook AR, Shankaran S, Finer NN, Carlo WA, Kennedy KA, Fridriksson JH, Steinhorn RH, Sokol GM, Konduri GG, Aschner JL, Stoll BJ, D’Angio CT, Stevenson DK (2005) Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med 353(1):13–22PubMedGoogle Scholar
  198. Vida VL, Gaitan G, Quezada E, Barnoya J, Castaneda AR (2007) Low-dose oral sildenafil for patients with pulmonary hypertension: a cost-effective solution in countries with limited resources. Cardiol Young 17(1):72–77PubMedGoogle Scholar
  199. Villanueva ME, Zaher FM, Svinarich DM, Konduri GG (1998) Decreased gene expression of endothelial nitric oxide synthase in newborns with persistent pulmonary hypertension. Pediatr Res 44:338–343PubMedGoogle Scholar
  200. Vukcevic Z, Coppola CP, Hults C, Gosche JR (2005) Nitrovasodilator responses in pulmonary arterioles from rats with nitrofen-induced congenital diaphragmatic hernia. J Pediatr Surg 40(11):1706–1711PubMedGoogle Scholar
  201. Walsh-Sukys MC, Tyson JE, Wright LL, Bauer CR, Korones SB, Stevenson DK, Verter J, Stoll BJ, Lemons JA, Papile LA, Shankaran S, Donovan EF, Oh W, Ehrenkranz RA, Fanaroff AA (2000) Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 105:14–20PubMedGoogle Scholar
  202. Wedgwood S, Lakshminrusimha S, Fukai T, Russell JA, Schumacker PT, Steinhorn RH (2011) Hydrogen peroxide regulates extracellular superoxide dismutase activity and expression in neonatal pulmonary hypertension. Antioxid Redox Signal 15(6):1497–1506PubMedCentralPubMedGoogle Scholar
  203. Wedgwood S, Lakshminrusimha S, Czech L, Schumacker PT, Steinhorn RH (2013) Increased p22(phox)/Nox4 expression is involved in remodeling through hydrogen peroxide signaling in experimental persistent pulmonary hypertension of the newborn. Antioxid Redox Signal 18(14):1765–1776PubMedCentralPubMedGoogle Scholar
  204. Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ (2004) Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 110(6):660–665PubMedGoogle Scholar
  205. Zwissler B, Welte M, Messmer K (1995a) Effects of inhaled prostacyclin as compared with inhaled nitric oxide on right ventricular performance in hypoxic pulmonary vasoconstriction. J Cardiothorac Vasc Anesth 9(3):283–289PubMedGoogle Scholar
  206. Zwissler B, Rank N, Jaenicke U, Schürle B, Welte M, Reichart B et al (1995b) Selective pulmonary vasodilation by inhaled prostacyclin in a newborn with congenital heart disease and cardiopulmonary bypass. Anesthesiology 82:1512–1516PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Pediatric Cardiology UnitDepartment of Pediatrics, Children’s University Hospital GenevaGeneva 14Switzerland
  2. 2.Department of Pediatrics, UC Davis Children’s Hospital, University of California, DavisSacramentoUSA

Personalised recommendations